The data show that current testing standards may not be sufficient in identifying women who are most at risk. The ATHENA trial proved that primary HPV screening is an effective strategy for determining the likelihood that women age 25+ will develop high-grade cervical disease.
Click the infographics below to explore the landmark trial
Interested in learning more?
Sign up to receive the latest news and updates on the FDA-approved cobas® HPV Test from Roche.